for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Morphic Holding Inc

MORF.OQ

Latest Trade

64.28USD

Change

-0.38(-0.59%)

Volume

679,887

Today's Range

61.69

 - 

65.00

52 Week Range

22.10

 - 

93.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
64.66
Open
63.81
Volume
679,887
3M AVG Volume
4.15
Today's High
65.00
Today's Low
61.69
52 Week High
93.00
52 Week Low
22.10
Shares Out (MIL)
36.21
Market Cap (MIL)
2,327.86
Forward P/E
-30.38
Dividend (Yield %)
--

Next Event

Morphic Holding Inc Annual Shareholders Meeting

Latest Developments

More

Morphic Holding Q1 Loss Per Share $0.63

Morphic Therapeutic Announces Proposed Public Offering

Morphic Announces Positive Preliminary Results From Phase 1 SAD Clinical Trial Of MORF-057

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Morphic Holding Inc

Morphic Holding, Inc is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially first-in-class oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company is advancing its preclinical pipeline, including its lead wholly-owned program for alpha 4 and beta 7-specific integrin inhibitors affecting inflammation into clinical development for the treatment of inflammatory bowel disease (IBD). It is also developing MORF-720, a selective oral specific integrin inhibitor into clinical development for the treatment of idiopathic pulmonary fibrosis (IPF).

Industry

Biotechnology & Drugs

Contact Info

35 Gatehouse Dr # A2

WALTHAM, MA

02451-1215

United States

+1.978.7296480

Executive Leadership

Gustav A. Christensen

Independent Chairman of the Board

Praveen P. Tipirneni

President, Chief Executive Officer, Director

Timothy A. Springer

Founder, Independent Director

Marc Schegerin

Chief Financial Officer, Chief Operating Officer

Robert E. Farrell

Senior Vice President - Finance, Chief Accounting Officer

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2019

-2.690

2020

-1.470

2021(E)

-2.116
Price To Earnings (TTM)
--
Price To Sales (TTM)
54.62
Price To Book (MRQ)
6.30
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-16.04
Return on Equity (TTM)
-14.39

Latest News

Latest News

BRIEF-Morphic Holding Inc Files For Mixed Shelf Of Up To $400 Million

* MORPHIC HOLDING INC FILES FOR MIXED SHELF OF UP TO $400 MILLION – SEC FILING Source text: [ID:https://bit.ly/3ik2wys] Further company coverage:

BRIEF-Morphic Therapeutic Presents Positive Preclinical Data For MORF-057 In Inflammatory Bowel Disease

* MORPHIC THERAPEUTIC PRESENTS POSITIVE PRECLINICAL DATA SUPPORTING DEVELOPMENT OF MORF-057 IN INFLAMMATORY BOWEL DISEASE AT DIGESTIVE DISEASE WEEK 2020 Source text for Eikon: Further company coverage:

BRIEF-Morphic Appoints Marc Schegerin As Chief Financial Officer, Chief Operating Officer

* MORPHIC ANNOUNCES APPOINTMENT OF MARC SCHEGERIN, M.D., AS CHIEF FINANCIAL OFFICER AND CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up